To start your customized experience click the start button
Customize ?  
Cancer Types
Quick Links
Award Programs
About Us
Contact Us
Privacy Policy
Terms & Conditions
Face Book
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Lung Cancer

Kristie L. Kahl
The IMpower133 trial demonstrated the added overall and progression-free survival benefits of adjuvant Tecentriq with standard of care therapy for patients with extensive-stage small cell lung cancer.
Kristie L. Kahl
In a recent survey, lung cancer survivors reported long-term symptoms, including shortness of breath, fatigue, short-term memory and anxiety.
Kristie L. Kahl
Patient-caregiver communities focused on non-small cell lung cancer with genomic alterations offer support, awareness and education to help accelerate research in this space.
Brielle Urciuoli
With new therapies that can target specific genetic mutations in patients with lung cancer, testing the tumor’s makeup is becoming increasingly important, according to Joshua Bauml, M.D.
Beth Fand Incollingo
From an inaugural gathering in 2009 that attracted approximately 700 people, the Life and Liberty event has grown in size each year, with more than 4,000 patients in attendance at last September’s celebration. Organizers said about 6,000 were there this year.
Jessica Skarzynski
A new blood test may offer a less invasive alternative to tissue testing when identifying patients with non-small cell lung cancer (NSCLC) who could benefit from certain immunotherapies.
Brielle Urciuoli
An expert discusses tips on how patients with cancer can manage their "scanxiety."
Kristie L. Kahl
The Food and Drug Administration (FDA) granted priority review to Keytruda (pembrolizumab) monotherapy for the first-line treatment of patients with locally advanced or metastatic nonsquamous or squamous non-small cell lung cancer (NSCLC) whose tumors express PD-L1 without EGFR or ALK genomic tumor aberrations.
Kristie L. Kahl
A small study showed that, despite national guideline recommendation, conversations between doctors and patients about the benefits and harms of lung cancer screening in those who are at high risk are not happening the way they should be.

Sign In

Not a member? Sign up now!
Continue without login

Sign Up

Patient Caregiver Advocate Other